We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Therapy for HIV Patients Failing Previous Therapy

By HospiMedica staff writers
Posted on 02 Oct 2000
In preclinical studies, the non-nucleoside reverse transcriptase inhibitor (NNRTI) capravirine demonstrated a potent antiviral activity against wild-type HIV as well as HIV strains with mutations in reverse transcriptase, such as K103N, that confer broad viral resistance to other NNRTIs to which patients failing treatment may have been exposed. More...


In clinical studies of treatment-naive patients, capravirine showed antiretroviral activity when used alone for a short period of time, and achieved target antiretroviral concentrations in plasma as a part of a combination therapy. A new double-blind 48-week study will evaluate capravirine for use in two groups of HIV-infected patients: those who have never been treated with anti-HIV medications and those who have failed previous treatment. Capravirine, which has been generally well tolerated by patients, was developed by Agouron Pharmaceuticals, Inc. (Toronto, Canada).



Related Links:
Agouron Pharmaceuticals

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Surgical System
Stealth AXiS
New
Hypodermic Syringe
SurTract™ Safety Syringe
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Allevion Medical receives FDA Clearance for Vantage, introducing a fully disposable approach to minimally invasive spinal decompression (photo courtesy of Allevion Medical)

Single-Use System Enables Minimally Invasive Decompression for Lumbar Spinal Stenosis

Lumbar spinal stenosis is frequently driven by hypertrophic bone that narrows the canal and produces pain. Conventional decompression often relies on larger incisions and bulky retractors, adding time,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.